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Abstract 
 
Purpose of Review: Primary sclerosing cholangitis (PSC) is progressive biliary liver disorder 
strongly associated with inflammatory bowel disease (PSC-IBD). We summarize the genetics of 
PSC-IBD and highlight recent findings that further differentiate PSC-IBD as a unique disease.  
  
Recent findings: To date, genome-wide studies have uncovered 23 susceptibility loci for PSC-
IBD; the majority of which have been previously reported as risk factors in other immune-
mediated disorders. For most candidates, the pathological relationship to PSC-IBD remains 
largely unknown. Several of candidate genes appear to be liver-related but the large majority 
relate to immunity and reaffirm that alterations to immune function, trafficking and tolerance are 
likely to influence susceptibility and presentation of PSC-IBD. Similar to most immune-mediated 
diseases, the strongest association in PSC-IBD resides within the human leukocyte antigen 
(HLA) complex and suggests that disease-specific antigens drive pathogenic immune responses. 
Although genetic predisposition influences disease, genetic determinants account for less than 
10% of total disease liability in PSC-IBD, clearly emphasizing the predominant role of 
environmental factors on disease susceptibility. 
 
Summary: Genetic studies define PSC-IBD as a unique disease to IBD mirroring clinical 
observations. Most risk loci harbour immune-related genes and disease variants are likely to 
perturb immune function, tolerance and/or trafficking. Additional studies in patients and novel 
experimental systems are needed to identify the origin and impact of environmental factors in 
relation to genetic predisposition in PSC-IBD. 
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Introduction 
 
Primary sclerosing cholangitis (PSC) is an enigmatic liver disorder marked by biliary infiltration 
and bile duct strictures leading to recurrent cholestasis, cirrhosis and end-stage liver disease. 
Characteristic inflammatory and obliterative concentric periductal fibrosis (“onion-skinning”) can 
affect both intrahepatic (small) and extrahepatic (large) bile and in 50-80% of cases clearly 
associates with a distinct form of inflammatory bowel disease (PSC-IBD) that features rectal 
sparing, backwash ileitis and right-sided predominance [1]. In line with clinical observations, 
genetic studies show that PSC-IBD shares limited overlap with IBD (~50%) and is driven by a 
unique set of genetic determinants compared to ulcerative colitis (UC) [2,3**,4**]. Whilst PSC 
in the absence of IBD may reflect true endotypes – subtypes of a condition defined by distinct 
pathological mechanisms – all patients may in fact experience mild colitis which is simply 
undetectable by current techniques. 
 
In early disease, patients with PSC-IBD typically present with elevated serum alkaline 
phosphatase (ALP) activity, often in the context of asymptomatic cholangitis and at later stages, 
fatigue, pruritus, splenomegaly, hepatomegaly and jaundice are common [5]. PSC-IBD carries an 
elevated risk of cancer and 10-20% of patients develop some form of hepatobiliary or colorectal 
malignancy [6,7*]. Incidence (0.9-1.3 per 100,000) and prevalence (8.5-13.6 per 100,000) of 
disease is increasing and varies geographically emphasizing that environmental factors 
significantly affect disease susceptibility [8,9]. Onset is generally between 30-40 years of age and 
unlike most autoimmune disorders, PSC-IBD affects males more frequently than females (2:1). 
Heritability is comparable to other complex immune-mediated disorders as first-degree relatives 
are 10-times more likely to develop PSC-IBD compared to unrelated individuals [10]. Effective 
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medical treatments are a critical unmet clinical need as the basic pathophysiology of PSC-IBD is 
poorly understood and liver transplantation remains the only means of managing disease 
progression [11]. 
 
 
Genetic studies in PSC-IBD 
 
Over the last decade, genome-wide association studies (GWAS) and targeted genotyping arrays 
have identified dozens of genes linked to the development (susceptibility genes) and phenotype 
(modifier genes) of PSC-IBD [2,3**,4**,12-16]. To date, these large-scale case-control 
investigations have uncovered a total of 23 risk loci of genome-wide significance (Table 1), most 
notably a striking human leukocyte antigen (HLA) association that closely resembles prototypical 
autoimmune disorders such as rheumatoid arthritis (RA), type 1 diabetes (T1D) and coeliac 
disease (CD) [17]. Weaker associations exist for the non-HLA loci and the majority of genes 
within these regions relate to immune pathways which all have been previously identified as risk 
loci in other immune-related diseases [18], a genetic term known as pleiotropy [19]. 
 
 
Non-HLA loci in PSC-IBD have small effect sizes that overlap with other immune-mediated 
conditions 
 
As the number of gene associations in PSC-IBD expands, the translation of these discoveries into 
disease biology remains challenging as none of the candidate genes harboured within these 
regions confer independent causality and considerable genetic heterogeneity exists in complex 
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disease [20]. For example, ASAP2 and NFKB1 associations were recently identified for PSC-IBD 
[16] suggesting ASAP2-mediated phagocytosis by innate cells [21*] and the myriad of NFK1B-
mediated processes in B and T cells have a role in pathogenesis [22]. Likewise, associations for 
BACH2 were previously reported [2] and recent data showing that BACH2 regulates the 
transition of lymphoid cells into memory lineages [23*,24*] similarly implies contributions of 
adaptive immunity to PSC-IBD. Although appealing, it is speculative to assign a precise 
pathogenic role to any of the gene associations in PSC-IBD since none of the loci point towards 
an obvious biological process, which differs from the primary biliary cholangitis (PBC), where 
disease-specific auto-antibodies to mitochondrial antigens (anti-mitochondrial antibodies; AMA) 
and associations affecting multiple pathways of immune tolerance [25] more clearly delineate 
PBC as autoimmune. Moreover, in contrast to monogenic disorders where a strong 
penetrance/causality exists, variants associated with complex disease have small effect sizes 
exemplified by the fact healthy individuals carrying multiple risk variants never develop disease. 
  
In lieu of causality, several important concepts have emerged from genetic studies in PSC-IBD 
that have been useful for the validation of clinical observations and prioritization of future 
research. First, cross-disease studies show that PSC-IBD is genetically distinct to IBD as less 
than half of the risk loci overlap between diseases and most of these associations are stronger in 
PSC-IBD than in IBD [2,3**,4**]. As the co-morbidity of IBD with PSC is reported in up to 
80% of cases, the restricted overlap between risk loci is surprising and could be interpreted to 
suggest that the shared associations are key drivers of IBD or that PSC-IBD is indeed a unique 
disease that manifests both colonic and biliary phenotypes. Neither scenario is mutual exclusive 
however clinical observations and recent genetic data supports the latter explanation whereby 
PSC-IBD is distinct to IBD but shares a certain degree of genetic similarity [2,3**,4**]. 
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Second, consistent with prevailing notions that PSC-IBD is autoimmune in nature, risk loci for 
PSC-IBD show considerable genetic overlap with archetypical autoimmune disorders such CD, 
T1D, multiple sclerosis and ankylosing spondylitis [2,3**,4**]. Again, genetic studies mirror 
clinical practice as patients with PSC-IBD are known to present with a higher co-incidence of 
immune-mediated diseases [26,27], implying that the pleiotropic loci in PSC-IBD may belong to 
a general pool of predisposing autoimmune risk factors. These finding also support a model of 
disease alongside the HLA association whereby currently unknown disease-specific antigens and 
auto-antibodies trigger or worsen progression PSC-IBD prior to the development of cholestasis 
and bile-acid toxicity. Lastly, several PSC-IBD loci, including BACH2, CD226, IL-2/IL-21 and 
MST1, are highly pleiotropic, associating with UC, Crohn’s disease, T1D, C1D, RA and alopecia 
areata [2,3**,4**]. The pleiotropism of these loci are likely indicative of common perturbations 
that promote the onset of immune-mediated conditions. Hence, insights gained from studying any 
of these diseases, particular the pathways relating to shared loci, may yield relevant 
considerations for disease biology and etiologies in PSC-IBD. 
 
Collectively, the genetic risk in PSC-IBD is estimated to account for less than 10% of total 
disease liability and comparable to other complex, polygenic immune-mediated diseases (ex. 
13.5% for Crohn’s disease, 7.5% for UC) [18]. Better assessment of genetic risk will require 
larger GWAS cohorts and the application of whole exome and genome sequencing technologies 
to identify rare variants of potentially large effect size given that genome-wide surveys are biased 
towards the detection of common alleles carried by greater than 1 – 5% of the general population. 
The modest contribution of GWAS loci to PSC-IBD emphasizes that non-genetic determinants of 
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unknown origin, presumably individual diet, toxin exposure, infection and microbiota, underpin 
disease susceptibility and phenotype on a backdrop of genetic predisposition. 
 
 
HLA association, TCR sequencing analysis and auto-antibody profiling points towards 
disease-specific antigenic triggers in PSC-IBD 
 
HLA associations are implicated in nearly every immune-mediated disorder but their relevance to 
disease biology has proven difficult to reconcile. In some instances such as T1D and CD, HLA 
associations have been shown to correlate with the presentation of tissue-specific antigens that 
elicit the activation and proliferation of pathogenic T cells [10,28,29]. For PSC-IBD, HLA 
associations reported by GWAS confirm earlier reports of such associations [28,29] and refined 
mapping of the HLA locus has identified HLA-B8 (HLA class I) and HLA-DRB1 (HLA class II) 
as the predominant risk alleles in PSC-IBD [17]. HLA-B8 and HLA-DRB1 are linked to many 
autoimmune conditions which supports the notion that breakdown of immune tolerance leads to 
immune-mediated hepatobiliary destruction [30].  
 
The robust HLA association and chronic infiltration of immune cells in areas of hepatobiliary 
injury suggests disease-specific antigens are responsible for driving pathogenesis in PSC-IBD. 
Consistent with this hypothesis, T-cell receptor (TCR) sequencing analysis of the liver-
infiltrating T cells in PSC-IBD explants has detected evidence of antigen-driven clonal expansion 
and presence of disease-associated clonotypes [31**]. TCR sequencing analysis has also 
demonstrated that memory T cells of common clonal origin are found at a higher frequency in 
paired gut and liver samples of PSC-IBD patients compared to controls [32**], implying 
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antigenic triggers (microbial, dietary or endogenous) may originate from the gut and enter the 
liver via the portal circulation to initiate or perpetuate immune activation [7*,33**]. 
 
In several immune-mediated diseases such as CD, RA and PBC, disease-specific auto-antibodies 
serve as clinical diagnostic biomarkers and have been used to identify disease-relevant antigens 
and dissect the role of specific HLA associations in pathogenesis [34-36]. For PSC, auto-
antibodies to biliary and colonic antigens as well as neutrophil granulocytes (perinuclear anti-
neutrophil cytoplasmic antibodies; pANCA) have been reported in patient sera however none of 
these reactivities demonstrate robust validation or disease specificity [37,38]. Antibody profiling 
of liver-infiltrating B cells from PSC-IBD explants has identified several novel reactivities of 
potential relevance however these findings require additional validation in large multi-centre 
study cohorts [39**]. Importantly, such studies using high-throughput technologies may be 
useful for identifying additional disease-specific auto-antibodies for PSC-IBD and alongside 
TCR cloning and HLA antigen-elution, aid the characterization of key molecules applicable for 
the development of tolerizing immunotherapy [40*]. 
 
 
Host genetic factors affect the composition of gut microbiota 
 
Although the breakdown of immune tolerance and activation of self-reactivity are probable 
mechanisms of disease in PSC-IBD, understanding how environmental factors drive the 
development of autoimmunity is poorly recognized. As gut commensals are known to regulate 
immune function and bile acid metabolism [41,42], the dysbiosis detected in both fecal and 
mucosal samples of patients with PSC-IBD may be indicative of an environmental risk for the 
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development of autoimmunity [33,43-44,45*46**]. Intriguingly, several recent studies in both 
humans [47**,48**] and mice [49-51] indicate host genetics, particularly the variability 
associated with immune genes, influences the composition of gut microbiota which implies that 
variants associated with disease may predispose individuals to gut dysbiosis that promotes 
autoimmunity. For PSC-IBD, variants of the suspected risk gene FUT2 are known to alter the 
biliary microbiome in PSC-IBD [14] and it remains to be seen if the dysbiosis in PSC-IBD is 
caused by genetic factors or by non-genetic determinants such as diet. Nevertheless, these 
findings raise the possibility that gut dysbiosis in the context of genetic predisposition may sway 
the colonization of gut mucosa from healthy to pathogenic in patients with PSC-IBD. Given that 
gut commensals are sensitive to diet and medical interventions [52**,53**], targeted alterations 
of the gut microbiome in conjunction with fecal microbiota transplant from healthy individuals 
may lessen or ameliorate disease. 
 
Certain functional characteristics of gut commensals are expected to underlie individual host-
microbe interactions therefore future studies utilizing meta-genomics with traditional 16s RNA 
sequencing may better detect the subtle functional differences that influence pathogenesis. 
Caution should be taken when using stool samples for the assessment of disease-associated 
microbes as fecal microbiota represent a mixture of mucosal microbes from the colon and lumen 
[54] and microbes enriched in stool may not be present or pathogenic at the active sites of liver 
and gut inflammation. As the intimate interactions between the microbiome and mucosal surfaces 
may be absent in stool, efforts to study the most appropriate tissue from PSC-IBD patients, 
genetically similar pathologies (IBD, Crohn’s disease) and other chronic autoimmune and 
metabolic liver diseases (PBC, autoimmune hepatitis, alcoholic liver disease, non-alcoholic 
steatotic hepatitis) should be prioritized when possible. 
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Conclusion 
 
A total of 23 susceptibility loci have now been identified for PSC-IBD and larger GWAS using 
well-phenotyped cohorts will further define the genetic architecture of PSC-IBD. From these 
insights, effects of specific variants can be mechanistically evaluated in experimental models 
which should lead to a greater understanding of the fundamental pathways underlying disease 
susceptibility and severity. As genome-wide surveys are limited to detect common variants, 
whole exome and genome sequencing studies as well as meta-data and epigenetic analyses will 
be important approaches for studying familial presentations and dissecting PSC endotypes.  
Emerging evidence suggests that genetic variability of the host, particularly in genes relating to 
immune function, influence gut microbiota indicating that a better understanding of this 
association in PSC-IBD may unlock tractable therapeutic targets. 
 
Immunogenetic discoveries whilst exciting have continued to however be a challenge to translate 
into therapeutic advances. This is because disease manifestation and the impact for a patient go 
far beyond the triggers of disease, and capture both the consequence of tissue damage, and the 
response to injury, alongside a presumed variation in environmental triggers. What determines a 
patient’s clinical course is therefore multi-faceted and dynamic. Genetic association studies 
identify pathways that contribute to risk, but the singular impact is usually unclear, with 
composite risk difficult to measure, and individual patient presentation in the absence of genetic 
risk frequent. This is further relevant to cholestatic liver diseases where disease cause and disease 
consequence need not parallel, and disease treatments that traditionally have focused on the 
consequence of cholestasis have proved effective in some settings, whilst clearly not tackling 
fundamental disease triggers. New therapies may therefore be identified by capturing broad 
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pathways to disease and its response, but the hope that individual gene loci become therapeutic 
targets is less probable. 
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Key points 
 
1. PSC-IBD is clinically and genetically distinct from IBD. 
 
2. HLA associations are the strongest risk loci in PSC-IBD and point towards disease-
specific antigenic triggers. 
 
3. Non-HLA associations for PSC-IBD are pleiotropic and predominantly correspond to 
immune-related genes. 
 
4. Risk loci in PSC-IBD may affect the composition of gut commensals that influence 
development and severity of disease. 
 
5. Translating genetic discoveries into relevant biology and therapeutics for complex 
diseases such as PSC-IBD remains challenging. 
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Tables 
 
Table 1. Risk loci in PSC-IBD. 
 
 
Study Year Study design Cohort ethnicity Patients (n) 
Controls 
(n) Risk loci (P < 5 x 10
-8) 
Karlsen et al. [12] 2010 GWAS Northern European 285 298 HLA 
Melum et al. [13] 2011 GWAS Northern European 
Central European 
European American 
1740 5136 BCL211, MST1, HLA, 
Srivastava et al. [15] 2012 targeted genotyping Northern European 992 5162 IL2RA, MST1 
Folseraas et al. [14] 2012 GWAS Northern European 
Central European 
European American 
1936 6470 TNFRSF14/MMEL1 
Ellinghaus et al. [16] 2013 GWAS Northern European 
Central European 
1401 5530 GPR35, TCF4 
Liu et al. [2] 
 
2013 targeted comparative 
analysis 
(Immunochip) 
Pan-European 3789 25,079 BACH2, CD226, 
CD28, HDAC7, HLA, 
IL2/IL2, IL2RA, 
MST1, 
PRKD2/STRN4, 
PSMG1, 
TNFRSF14/MMEL1, 
SH2B3/ATXN2, SIK2 
Ellinghaus et al. [3] 
 
2016 targeted comparative 
analysis 
(Immunochip) 
Pan-European 3,408 34,213 ASAP2, NFKB1, 
RIC8B, 
LOC107984859  
Ji et al. [4] 
 
2016 GWAS Northern European 
European American 
African 
Han Chinese 
Japanese 
4,796 19,955 CCDC88B, 
CLEC16A, FOXP1, 
UBASH3A 
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